Search results for " vaccines" in Articles / App Notes
Article
Technologies and Practices Must Evolve to Meet Demand
A majority of survey respondents work for organizations that develop and manufacture large-molecule drugs, both small- and large-molecule therapies, and vaccines; more than 18% indicated that their or…
Article
Challenges and Trends in Biopharma Facility Design
Kranjac (Cytiva): Beyond monoclonal antibodies, adapting modern flexible, modular construction and single-use processes towards the efficient production of vaccines and other biomolecules is a key tre…
Article
Healthcare Reform in China
Chinese healthcare reforms may be a double-edged sword for foreign companies.
Sep 1, 2014
By: Jane Wan
BioPharm International
Volume 27, Issue 9, pp. 8-12
On March 25, 2014, the…
Article
Challenges of Protein Aggregation During Purification
Careful selection of downstream processing conditions is a must.
Sep 1, 2014
By: Cynthia Challener, PhD
BioPharm International
Volume 27, Issue 9, pp. 32-35
Removal of protein a…
Article
Single-Domain Antibodies for Brain Targeting
Single-domain antibodies are emerging as credible alternatives due to their target specificity, high affinity, and cost-effective recombinant production.
Smaller recombinant antibody fragments a…
Article
Challenges in Analytical Method Development and Validation
For example, patient-specific cancer vaccines require conceptually a different approach in that some (routine) test methods should test for non-patient-specific manufacturing (batch-to-batch) consiste…
Article
Trends in BioPharma Approvals in 2013
In 2013, 20 products containing new biopharmaceutical molecular entities (defined herein as recombinant proteins, monoclonal antibody or biosynthesized nucleic acid-based products) were approved in t…
Article
Brazil Emerges as Global Biopharm Collaborator
Such measures have traditionally been used for vaccines and most recently for synthetic drugs as well as biopharmaceutical products.
Future growth
The global financial crisis, which starte…
Article
2014 Manufacturing Trends and Outlook
More than 40% of the respondents said their companies manufacture vaccines; 17.7% develop cells for tissue and/or cell therapies; 10.4% manufacture nucleic-acid based drugs.
Challenges: Protein…
Article
Trends in Downstream Bioprocessing
Downstream processing involves the recovery and purification of protein therapeutics for biopharmaceuticals, vaccines, and other biologics. It involves the removal of insoluble cell debris and parti…